secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMGC Holdings Inc. (ELAB)
CIK:        0001840563
Form:       8-K
Filed at:   2025-04-10T23:59:59+00:00
Accession:  0001213900-25-030640
Event type: m_and_a
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMGC subsidiary Northstrive licenses Yuva Biosciences' AI platform for obesity and cardiometabolic drugs
--------------------------------------------------------------------------------

- Northstrive (PMGC subsidiary, ticker ELAB) signs exclusive worldwide license for therapies in cardiac diseases and obesity.
- YuvaBio to use its AI platform MitoNova to identify small molecule candidates targeting mitochondrial health.
- Upfront fee, development milestone payments, and tiered royalties on net sales; no specific dollar amounts disclosed.
- Multi-phase program includes in silico modeling, virtual screening, and wet-lab validation to shortlist candidates.
- Agreement covers multi-year term; Northstrive may terminate for convenience with early termination fee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840563/000121390025030640/0001213900-25-030640-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840563/000121390025030640/ea0237224-8k_pmgchold.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-030640

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer